13F reference period
Q2 2026
Security Snapshot
Cadrenal Therapeutics, Inc. - Common Stock (CVKD) Institutional Ownership
CUSIP: 127636207
13F Institutional Holders and Ownership History from Q3 2024 to Q3 2026
Institutions Reporting
16
Shares (Excl. Options)
112.36K
Full value: 112,364 · shares · 30 Jun 2026Price
$3.34
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- CVKD on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 112,364
- Total 13F value
- $375,253
- Portfolio coverage rank
- 0%
- Share change
- +21,426
- Value change
- +$51,534
- Number of holders
- 16
- Shares outstanding
- 2,868,622
- SEC-reported price per share
- $1.08
- Insider filing price
- $1.08
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- CVKD - Cadrenal Therapeutics, Inc. - Common Stock is tracked under CUSIP 127636207.
- 16 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 17 to 16 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$459.44K
Full value: $459,437 · USD · 31 Mar 2026.$375.25K
Full value: $375,253 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 16 institutions filings for Q2 2026.
Security key
127636207
13F reference period
Q2 2026
13F holders
16
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
CVKD full holder history
Cadrenal Therapeutics, Inc. SEC filings
Cadrenal Therapeutics, Inc. company facts
Cadrenal Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 127636207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
CVKD
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Pham Quang X | 24% | $7,115,610 | 421,042 | Quang X. Pham | 23 Jan 2025 | |||
| PNC FINANCIAL SERVICES GROUP, INC. | 8.1% | $739,304 | 233,219 | The PNC Financial Services Group, Inc. | 30 Jun 2026 | |||
| Havlickova 648 a.s. | 4.4% | $1,323,118 | 78,291 | Havlickova 648 a.s. | 31 Dec 2024 | |||
| MURPHY JOHN RAYMOND | 3% | $899,164 | 53,205 | John Raymond Murphy | 31 Dec 2024 |
As of 30 Jun 2026,
16
institutional investors reported holding
shares of
Cadrenal Therapeutics, Inc. - Common Stock (CVKD).
This represents
3.9%
of the company’s total
outstanding shares.
112.36K
Full value: 112,364 · shares · 30 Jun 20262.87M
Full value: 2,868,622 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
9
Headline period
Q2 2026
Rows shown
1-9 of 9
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 20,867 | $22,536 | +$21,424 | $1.08 | 3 |
| 2026 Q2 | 112,364 | $375,253 | +$51,534 | $3.34 | 16 |
| 2026 Q1 | 90,938 | $459,437 | -$217,622 | $5.12 | 17 |
| 2025 Q4 | 121,486 | $823,673 | -$90,750 | $6.78 | 18 |
| 2025 Q3 | 114,193 | $1,573,701 | +$635,888 | $13.83 | 17 |
| 2025 Q2 | 68,347 | $823,305 | -$12,430 | $12.05 | 14 |
| 2025 Q1 | 69,304 | $1,221,972 | +$961,600 | $17.63 | 13 |
| 2024 Q4 | 14,845 | $215,103 | +$214,451 | $14.49 | 9 |
| 2024 Q3 | 5 | $68 | +$68 | $13.60 | 1 |